AKT1 and colorectal carcinoma: ISL, on the other hand, offers a natural and low-toxicity alternative, demonstrating the ability to downregulate FGFR4, suppress FASN, and inhibit the PI3K/Akt pathway—all key drivers of lipid metabolism and CRC progression.